Can Peripheral Blood Systemic Immune Response Parameters Predict Oncological Outcomes in Patients with Non‑Muscle‑Invasive Bladder Cancer?

Abstract

Background: Many studies have investigated most cancer types ‑ associations with systemic inflammatory response (SIR) parameters. Aim: This study investigated predictive values of SIR parameters in oncological outcomes and survival – to primary non‑muscle‑invasive bladder cancer (NMIBC) patients. Materials and Methods: We analyzed 74 primary NMIBC patients. Clinical features, laboratory results, and tumor characteristics were recorded. In addition, the neutrophil‑to‑lymphocyte ratio (NLR), monocyte‑to‑lymphocyte ratio (MLR), platelet‑to‑lymphocyte ratio (PLR), serum C‑reactive protein, albumin‑to‑globulin ratio (AGR), and modified Glasgow prognostic scores (mGPS) were calculated. Results: The ‑ mean age of the patients was ‑ 67.41 ± 11.31 years, and the follow‑up duration was 38.77 ± 19.53 months. We – found no significant NLR, CRP, and AGR – correlations with tumor characteristics and oncological outcomes. There were significant – correlations between MLR and pathological‑T‑stage and the PLR, pathological‑T‑stage, and tumor count. Carcinoma in situ was associated with a high mGPS. Multivariate analysis revealed no significant – correlations between systemic inflammatory response parameters and oncological outcomes. Patients with a high mGPS had poor cancer‑specific survival. Increased NLR was associated with reduced overall survival. Conclusions: This study revealed no significant correlation between SIR parameters and oncological outcomes. Therefore, we need more reliable indicators than SIR parameters in NMIBC patients in clinical practice.